A theoretical paper published in Psychopharmacology in 2026 proposes that anxiety disorders may involve a kind of stuck pattern in the hippocampus, a brain structure central to memory and context, and that psychedelics could work by temporarily disrupting that pattern. This is a theoretical framework, not a clinical trial, and no human therapeutic outcomes are […]
In an ongoing randomized clinical trial, researchers at the University of Colorado and New York University are studying whether a single 25-milligram dose of synthetic psilocybin, paired with preparatory and integration therapy sessions, can ease anxiety and depression in patients with advanced cancer. Results are not yet published. Key takeaways This is an active, enrolling […]
Kingston Health Sciences Centre in Ontario has launched a regulated clinical trial examining whether psilocybin-assisted therapy can reduce anxiety. The trial is in an early enrollment phase, and no outcome data have been reported yet. No conclusions about effectiveness can be drawn at this stage. Key takeaways A Canadian institution is now running this work: […]
A single 25 mg dose of psilocybin, given alongside structured psychological support, produced measurable reductions in depression and anxiety that held for up to two years in a group of cancer patients. Those are the findings of a phase 2 trial now published in Cancer, the peer-reviewed journal of the American Cancer Society, and they […]
A new open-label trial published in June 2026 offers some of the most encouraging data yet on psilocybin-assisted therapy veterans living with treatment-resistant depression. According to the study, a single oral dose of 25 milligrams of psilocybin was associated with a 59 percent reduction in anxiety scores at three weeks, and those improvements in anxiety, […]